Last Updated: 02/10/2025
Implementation evidence from health economics and users on preventing malaria in vulnerable children with monoclonal antibodies (HEKIMA)
Objectives
The objective of this study is to conduct costing and acceptability research for monoclonal antibody treatment (Mabs) in Kenya, Uganda, Malawi, and Benin to determine per country its cost-effectiveness, assess the public willingness to pay, and evaluate system readiness. Ultimately, the aim is to inform decision-makers and donors on the implementation of Mabs as a new standard for this vulnerable child population.
This consortium’s advocacy for antimalarial use in children under five has prompted a trial in Kenya testing monoclonal antibody treatment for post-discharge malaria prevention in children who have survived severe anaemia. This treatment, though more expensive, offers immediate efficacy with no side effects, potentially benefiting these children with a high mortality risk upon hospital discharge.
Jan 2025 — Dec 2029
$1.09M
Related Resources
